25+ Long COVID Phenotyping List
- Apr 8
- 9 min read
Updated: 5 days ago
Clinical and Social Terrain Subtypes in Long COVID
Executive Summary
For years, Long COVID, also referred to as post-acute sequelae of SARS-CoV-2 infection (PASC), has often been approached in research and clinical care as though it were a single condition. That framing has never fully matched the evidence. Long COVID is now widely recognized as a heterogeneous infection-associated chronic condition with variable symptom clusters, fluctuating severity, and relapsing, worsening, improving, or mixed trajectories over time (National Academies of Sciences, Engineering, and Medicine, 2024; Ely et al., 2024). This heterogeneity has major implications for diagnosis, care delivery, prevalence estimation, and therapeutic development.
A growing body of literature suggests that Long COVID involves overlapping but distinct patterns of dysfunction spanning post-exertional symptom exacerbation, autonomic instability, neurocognitive impairment, immune dysregulation, viral persistence or reactivation, cardiopulmonary symptoms, gastrointestinal disruption, endocrine shifts, sleep disturbance, and pain-related neurological excitability (Yong, 2021; Turner et al., 2023; Geng et al., 2024; Vlaming-van Eijk et al., 2025). When these patterns are not stratified, clinical trials risk mixing biologically different patient groups, reducing signal detection and obscuring treatment effects that may be relevant only to specific subpopulations.
The CYNAERA 25+ Long COVID Phenotyping List is designed as a structured classification model that integrates biological, environmental, functional, and social terrain variables into a practical phenotyping framework. It is not based on the assumption that Long COVID presents identically across patients. Instead, it reflects the current evidence that Long COVID is a multi-system condition whose presentation is shaped by interacting physiologic drivers, baseline vulnerability, environmental exposure, timing, and structural determinants of diagnosis and care (National Academies of Sciences, Engineering, and Medicine, 2024; Chen et al., 2024; Mir et al., 2025).
This framework is intended to support more adaptive clinical trial design, more precise phenotype-based care pathways, and more realistic modeling of underdiagnosed or structurally overlooked populations. It also aligns with a broader movement in Long COVID research toward identifying sub-phenotypes that can improve case definition, therapeutic targeting, and interpretation of outcomes across diverse patient groups (Geng et al., 2024; Vlaming-van Eijk et al., 2025).
Core Domains of Phenotyping
Long COVID behaves less like a single uniform diagnosis and more like a stressed and shifting system in which multiple biological pathways interact over time. The most important question is often not simply which symptoms are present, but which pattern is dominant, what triggers destabilization, and how function changes in response to exertion, infection, stress, environmental exposure, or endocrine transition (National Academies of Sciences, Engineering, and Medicine, 2024; Turner et al., 2023).
Formula: Phenotype = Core Axis × Trigger/Modulator + Functional Signature
These domains are CYNAERA-defined clinical and social terrain phenotypes informed by published evidence on Long COVID heterogeneity, fluctuating symptom courses, and overlapping pathophysiologic mechanisms, including post-exertional malaise, autonomic dysfunction, neurocognitive impairment, immune dysregulation, and disparities in recognition and access (National Academies of Sciences, Engineering, and Medicine, 2024; Yong, 2021; Turner et al., 2023; Geng et al., 2024; Mir et al., 2025).
1. Energy, Exertion & Recovery Axis
(Post-exertional symptom exacerbation and fluctuating recovery capacity are widely recognized as central features in Long COVID and related conditions) (National Academies of Sciences, Engineering, and Medicine, 2024; Geng et al., 2024)
PEM-Dominant Long COVID – exertion leads to delayed, multi-system symptom crash
Cognitive PEM Variant – mental exertion triggers relapse
Delayed-Onset PEM – flare occurs 24–72 hours after activity
Remission-Relapse Oscillator – alternating stable and crash states
Adrenergic Compensation Subtype – temporary function through stress-hormone overdrive, then collapse
2. Autonomic & Circulatory Axis
(Autonomic dysfunction, orthostatic intolerance, and circulatory instability are consistently reported across Long COVID cohorts) (Yong, 2021; Turner et al., 2023)
POTS-Dominant Long COVID – tachycardia, orthostatic intolerance, palpitations
Orthostatic Intolerance (Non-Tachycardic) – dizziness and fatigue without major HR spike
Blood Volume/Perfusion Variant – low plasma volume, poor circulation, cognitive slowing
Baroreflex Dysregulation – unstable blood pressure with positional stress
Air Hunger / Post-Exertional Dyspnea Variant – breathlessness linked to autonomic or exertional instability
3. Neurocognitive & Neuroinflammatory Axis
(Cognitive dysfunction, sensory sensitivity, and neuroinflammatory symptoms are among the most common Long COVID manifestations) (National Academies of Sciences, Engineering, and Medicine, 2024; Yong, 2021)
Neuroinflammatory Brain Fog – slowed processing, memory disruption, executive dysfunction
Sensory Overload Dominant – hypersensitivity to light, sound, smell, or motion
Cognitive-Motor Coordination Decline – impaired thinking and movement integration
Visual-Spatial Processing Deficit – delayed motion or spatial awareness
Neuroinflammatory Head Pressure – migraine-like symptoms and cognitive crashes
4. Immune Activation, Viral Persistence & Reactivation Axis
(Immune dysregulation, inflammatory signaling, and viral persistence/reactivation hypotheses are widely discussed in Long COVID pathophysiology) (Yong, 2021; Turner et al., 2023)
Viral Persistence-Suspected Long COVID – ongoing antigen or viral reservoir activity
Viral Reactivation Subtype – EBV, HHV-6, HSV, or similar reactivation linked to flares
Immune Fragility Variant – recurrent infections or poor immune recovery
Mast Cell Activation Overlap – histamine intolerance, flushing, airway reactivity, allergic-type symptoms
Steroid-Responsive or Steroid-Destabilized Pattern – variable response to immune suppression
5. Cardiovascular & Chest Symptom Axis
(Cardiovascular symptoms, chest pain, and exertional intolerance are commonly reported and often overlap with autonomic dysfunction) (Yong, 2021)
Palpitation-Dominant Long COVID – irregular heartbeat, tachycardia, adrenaline surges
Chest Pain / Pressure Subtype – inflammatory, vascular, or musculoskeletal chest discomfort
Exertional Cardiac Intolerance – activity triggers disproportionate symptom escalation
Residual Cardio-Pulmonary Injury Variant – lingering symptoms after cardiac or lung involvement
6. Gastrointestinal, Metabolic & Nutritional Axis
(Gastrointestinal disruption and metabolic instability are frequently observed and may contribute to disease severity and recovery limitations) (National Academies of Sciences, Engineering, and Medicine, 2024)
GI Dysmotility – nausea, bloating, constipation, diarrhea, or gastroparesis-like symptoms
Food Reactivity Subtype – symptom worsening with specific foods or histamine load
Malabsorption / Nutrient Depletion Variant – deficiencies worsening illness severity
Metabolic Instability – blood sugar dysregulation and energy crashes
7. Hormonal & Endocrine Axis
(Emerging evidence suggests endocrine and hormonal shifts influence symptom variability, particularly across sex and life stages) (Turner et al., 2023)
Cycle-Triggered Long COVID – symptom flares linked to menstrual cycle
Estrogen Withdrawal Subtype – worsening during perimenopause or menopause
Postpartum Long COVID – onset or worsening after childbirth
Hormone-Sensitive Variant – symptom shifts with endocrine changes or therapy
8. Sleep, Pain & Neurological Excitability Axis
(Sleep disruption, chronic pain, and neurological excitability frequently co-occur and contribute to functional decline) (National Academies of Sciences, Engineering, and Medicine, 2024; Yong, 2021)
Non-Restorative Sleep – unrefreshing sleep despite adequate duration
Circadian Rhythm Disruption – delayed or reversed sleep-wake cycle
Pain-Dominant Long COVID – neuropathic pain, headaches, muscle pain, body pressure
Neuro-Excitability Subtype – tremors, internal vibrations, startle, or sensory overactivation
9. Functional Severity & Disease Progression Axis
(Long COVID is characterized by fluctuating, relapsing, and progressive trajectories rather than static disease states) (National Academies of Sciences, Engineering, and Medicine, 2024; Ely et al., 2024)
Mild but Unstable Long COVID – outward function with frequent relapses
Housebound Intermittent – mobility preserved only through strict pacing
Severe / Bedbound Subtype – profound disability with major sensory and functional limitation
Multi-System Progression Variant – accumulation of new symptoms over time
Partial Remission but Fragile – improved baseline with high relapse risk
10. Social, Structural & Access-Constrained Modifiers
(Structural inequities, diagnostic bias, and access limitations significantly influence recognition, progression, and outcomes) (Chen et al., 2024; Mir et al., 2025) These do not define biological phenotype alone but strongly shape severity, diagnosis, and progression:
BIPOC Misdiagnosed Variant – symptoms dismissed, fragmented, or misclassified
Women Misdiagnosed as Anxiety – autonomic, immune, or endocrine symptoms minimized
Men Misdiagnosed as Burnout – underrecognized due to cultural and diagnostic assumptions
Pediatric Misattribution – symptoms mislabeled as behavioral, developmental, or psychological
Low-Income Access Barrier – delayed diagnosis and limited access to care
Mold / Environmental Exposure Overlay – smoke, mold, housing, or chemical triggers worsen symptoms
Food Insecurity Overlay – nutritional instability amplifies flares and recovery difficulty
Caregiver Constraint Overlay – inability to rest or pace due to family responsibilities
Medical Gaslighting Overlay – delayed care and progression shaped by repeated dismissal
Why This Matters
Clinical Trials
Stratifying Long COVID into clinically meaningful subtypes can improve signal detection, reduce misclassification, and support more targeted therapeutic development. This is especially important for interventions likely to work only in specific subgroups, such as those with dominant autonomic dysfunction, post-exertional symptom exacerbation, immune activation, or suspected viral persistence. Recent Long COVID research and definition work increasingly supports the need for sub-phenotyping rather than relying on a one-size-fits-all case construct for all research purposes (National Academies of Sciences, Engineering, and Medicine, 2024; Geng et al., 2024; Vlaming-van Eijk et al., 2025).
Clinical Care
Phenotype-based classification can improve care by helping clinicians distinguish whether a patient’s dominant instability is driven by exertional intolerance, dysautonomia, neurocognitive dysfunction, immune reactivity, endocrine fluctuation, respiratory symptoms, gastrointestinal disruption, or environmental aggravators. This matters because patient trajectories, tolerances, and treatment responses are often shaped by dominant mechanism patterns rather than by diagnosis alone (Yong, 2021; Turner et al., 2023).
Accuracy and System-Level Insight
Long COVID outcomes are shaped not only by biology but also by diagnostic timing, access to testing, environmental stressors, socioeconomic conditions, and the way race, ethnicity, sex, gender, age, and disability influence recognition within healthcare systems. Inclusive frameworks that account for these realities are more likely to improve prevalence estimation, support equitable diagnosis, and reduce false assumptions about who Long COVID affects and how it progresses (National Academies of Sciences, Engineering, and Medicine, 2024; Chen et al., 2024; Mir et al., 2025).
CYNAERA Framework Papers
This paper draws on a defined subset of CYNAERA Institute white papers that establish the methodological and analytical foundations of CYNAERA’s frameworks. These publications provide deeper context on prevalence reconstruction, remission, combination therapies and biomarker approaches. Our Long COVID, ME/CFS, Lyme and CRISPR Remission Libraries are also in depth resources.
Author’s Note:
All insights, frameworks, and recommendations in this written material reflect the author's independent analysis and synthesis. References to researchers, clinicians, and advocacy organizations acknowledge their contributions to the field but do not imply endorsement of the specific frameworks, conclusions, or policy models proposed herein. This information is not medical guidance.
Patent-Pending Systems
Bioadaptive Systems Therapeutics™ (BST) and affiliated CYNAERA frameworks are protected under U.S. Provisional Patent Application No. 63/909,951. CYNAERA is built as modular intelligence infrastructure designed for licensing, integration, and strategic deployment across health, research, public sector, and enterprise environments.
Licensing and Integration
CYNAERA supports licensing of individual modules, bundled systems, and broader architecture layers. Current applications include research modernization, trial stabilization, diagnostic innovation, environmental forecasting, and population level modeling for complex chronic conditions. Basic licensing is available through CYNAERA Market, with additional pathways for pilot programs, institutional partnerships, and enterprise integration.
About the Author
Cynthia Adinig is the founder of CYNAERA, a modular intelligence infrastructure company that transforms fragmented real world data into predictive insight across healthcare, climate, and public sector risk environments. Her work sits at the intersection of AI infrastructure, federal policy, and complex health system modeling, with a focus on helping institutions detect hidden costs, anticipate service demand, and strengthen planning in high uncertainty environments.
Cynthia has contributed to federal health and data modernization efforts spanning HHS, NIH, CDC, FDA, AHRQ, and NASEM, and has worked with congressional offices including Senator Tim Kaine, Senator Ed Markey, Representative Don Beyer, and Representative Jack Bergman on legislative initiatives related to chronic illness surveillance, healthcare access, and data infrastructure. In 2025, she was appointed to advise the U.S. Department of Health and Human Services and has testified before Congress on healthcare data gaps and system level risk.
She is a PCORI Merit Reviewer, currently advises Selin Lab at UMass Chan, and has co-authored research with Harlan Krumholz, MD, Akiko Iwasaki, PhD, and David Putrino, PhD, including through Yale’s LISTEN Study. She also advised Amy Proal, PhD’s research group at Mount Sinai through its CoRE advisory board and has worked with Dr. Peter Rowe of Johns Hopkins on national education and outreach focused on post-viral and autonomic illness. Her CRISPR Remission™ abstract was presented at CRISPRMED26 and she has authored a Milken Institute essay on artificial intelligence and healthcare.
Cynthia has been covered by outlets including TIME, Bloomberg, Fortune, and USA Today for her policy, advocacy, and public health work. Her perspective on complex chronic conditions is also informed by lived experience, which sharpened her commitment to reforming how chronic illness is understood, studied, and treated. She also advocates for domestic violence prevention and patient safety, bringing a trauma informed lens to her research, systems design, and policy work. Based in Northern Virginia, she brings more than a decade of experience in strategy, narrative design, and systems thinking to the development of cross sector intelligence infrastructure designed to reduce uncertainty, improve resilience, and support institutional decision making at scale.
References
Chen, Y., Rhoades, J., Khullar, D., et al. (2024). Racial and ethnic differences in long-COVID-associated symptoms and conditions among adults. eClinicalMedicine, 70, 102547.
Ely, E.W., Brown, L.M. and Fineberg, H.V. (2024). Long COVID defined. New England Journal of Medicine, 391(18), 1746–1753.
Geng, L.N., Erlandson, K.M., Hornig, M., et al. (2024). 2024 update of the RECOVER-Adult Long COVID Research Index. JAMA. doi:10.1001/jama.2024.24184.
Institute of Medicine. (2015). Beyond myalgic encephalomyelitis/chronic fatigue syndrome: Redefining an illness. Washington, DC: The National Academies Press.
Komaroff, A.L. and Lipkin, W.I. (2021). Insights from myalgic encephalomyelitis/chronic fatigue syndrome may help unravel the pathogenesis of post-acute COVID-19 syndrome. Trends in Molecular Medicine, 27(9), 895–906.
Mir, G., Mullard, J., Chew-Graham, C.A., et al. (2025). Addressing inequalities in Long Covid healthcare: A mixed-methods study on building inclusive services. Health Expectations. doi:10.1111/hex.70336.
National Academies of Sciences, Engineering, and Medicine. (2024). A long COVID definition: A chronic, systemic disease state with profound consequences. Washington, DC: The National Academies Press.
Turner, S., Khan, M.A., Putrino, D., Woodcock, A. and Pretorius, E. (2023). Long COVID: Pathophysiological factors and abnormalities of coagulation. Trends in Endocrinology and Metabolism, 34(5), 321–344.
Vlaming-van Eijk, L.E., van der Horst, I.C.C., van den Borst, B., et al. (2025). Post-COVID-19 condition: Clinical phenotypes and personalised medicine perspectives. European Journal of Internal Medicine, 139, 24–31.
Yong, S.J. (2021). Long COVID or post-COVID-19 syndrome: Putative pathophysiology, risk factors, and treatments. Infectious Diseases, 53(10), 737–754
Comments